FDA-Drug2026-04-22Class IIPROCESSING DEFECT
Payless Compounders semaglutide injectable recalled for sterility concerns
What this means
Payless Compounders is recalling a compounded semaglutide injection due to lack of assurance of sterility. The affected product is a 0.5 mL vial from lot 01-27-2026@14S.5 distributed in Oregon. No injuries have been reported so far.
- Stop using this product immediately if you have it
- Contact your pharmacy or healthcare provider with the lot number
- Do not use remaining doses from the affected lot
- Ask your provider about alternative treatment options
The agency's original wording
Hazard
Lack of Assurance of Sterility
Intended for
Adults
Illnesses reported
None reported
Sold states
OR
Affected count
91 vials
Manufactured in
8505 Sw Creekside Pl Ste 110, N/A, Beaverton, OR, United States
Products
Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0471-2026Want us to check the next one for you?
We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.